

Product datasheet for TA335167

CIITA Rabbit Polyclonal Antibody

Product data:

Product Type: Primary Antibodies

Applications: WB

Recommended Dilution: WB

Reactivity: Human

Host: Rabbit

Isotype: IgG

Clonality: Polyclonal

Immunogen: The immunogen for anti-CIITA antibody: synthetic peptide directed towards the middle region

of human CIITA. Synthetic peptide located within the following region: YNKFTAAGAQQLAASLRRCPHVETLAMWTPTIPFSVQEHLQQQDSRISLR

Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2%

sucrose.

Note that this product is shipped as lyophilized powder to China customers.

Purification: Affinity Purified

Conjugation: Unconjugated

Storage: Store at -20°C as received.

Stability: Stable for 12 months from date of receipt.

Predicted Protein Size: 123 kDa

Gene Name: class II, major histocompatibility complex, transactivator

Database Link: NP 000237

Entrez Gene 4261 Human

P33076



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



Background:

CIITA is a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class IIdeficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Sequence Note: This RefSeg record was created from transcript and genomic sequence data because no single transcript was available for the full length of the gene. The extent of this transcript is supported by transcript alignments. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

Synonyms: C2TA; CIITAIV; MHC2TA; NLRA


Note: Immunogen Sequence Homology: Pig: 100%; Human: 100%; Rat: 93%; Horse: 93%; Rabbit:

93%; Dog: 86%; Mouse: 86%; Guinea pig: 86%; Bovine: 79%

Protein Pathways: Antigen processing and presentation, Primary immunodeficiency



Product images:



WB Suggested Anti-CIITA Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 62500; Positive Control: Human Liver